# Shenzhen Dingbang Bioscience Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shenzhen-dingbang-bioscience-co

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Latest round: Series A (Jul 14, 2022)
- Investors on record: 1

## About

Established in 2019 and based in Shenzhen, China, Shenzhen Dingbang Bioscience Co., Ltd is a biopharmaceutical R&D company focused on stable isotope drug development, manufacturing, sales and service and medical devices. Xiaojun Yang will remain as CEO of Shenzhen Dingbang Bioscience Co., Ltd. In July 2022, the company raised an undisclosed amount of series A funding from new investor Yanghe Investment.

The company's main business is biopharmaceutical technology development, technology transfer, technology consulting, technology services, biomedical products technology development, technology transfer, technology consulting, technology services, engaged in the development of chemical and biological reagents, raw materials, intermediates and the wholesale of instruments and equipment, the development and sale of medical devices. The drugs under development by this company are mainly labeled by stable isotopes such as 2H, 10B, 13C and 18O, of which 2H (deuterium) is a medical imaging drug, used in clinical magnetic resonance (MR) molecular metabolic imaging, early screening and diagnosis of cancer (liver cancer, glioma and other metabolic tumors) and neurodegenerative diseases.

The company plans to use the series A funding to invest in the research and development of fixed isotope drugs and technological innovation.

## Funding rounds

- Series A, Jul 14, 2022 — Yanghe Biomedicine Industry Investment

## Investors

- Yanghe Biomedicine Industry Investment (https://capitalatlas.ai/funds/yanghe-biomedicine-industry-investment) — Series A